We are Sorry, This Page doesn't Exist

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies......»»

Shares of AstraZeneca were down 0.1% in trading on Monday after the drugmaker said it voluntarily withdrew an indication grant.....»»

Shares of Gilead Sciences Inc. were down 0.1% in premarket trading on Thursday, the day after the company said an experimental idiopathic pulmonary fibrosis drug it was developing with Galapagos failed a Phase 3 clinical trial. Shares o.....»»

Shares of AstraZeneca were up 0.6% in trading on Tuesday; this morning the .....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Shares of Biohaven Pharmaceutical Holding Company Ltd. tumbled 16% in premarket trading on Monday after the company said its experimental treatment for generalized anxiety disorder failed in a clinical trial. Patien.....»»

Shares of ImmunoGen Inc. gained 18% in afternoon trading after the biotechnology company announced that the Food and Drug Administration had cleared a trial for its investigational ovarian cancer drug to be used to supp.....»»

Bristol-Myers Squibb Co. shares slid 0.9% in premarket trade Wednesday, after the drug company said a trial of opdivo p.....»»

Merck KGaA and Pfizer said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival. The cur.....»»

AstraZeneca plc (NYSE: AZN) shares were advancing Monday following a clinical readout from the company. What Happened The U.K.-based pharma giant said its Phase 3 POSEIDON trial produced positive results.  read more.....»»

AstraZeneca plc (NYSE: AZN) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. read more.....»»

Bristol-Myers Squibb Co. said a phase 3 trial (CheckMate-548) evaluating its blockbuster cancer drug Opdivo as an addition to the current standard of care versus the st.....»»

Shares of Aridis Pharmaceuticals Inc. plunged 27% to pace all premarket decliners Tuesday, after the.....»»

Unum Therapeutics Inc (NASDAQ: UMRX) shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday. read more.....»»

Calithera Biosciences Inc (NASDAQ: CALA) shares were making a strong upward move Monday  following a clinical trial readout from the company. read more.....»»

AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial......»»

Shares of ImmunoGen Inc. led biotech’s losers on Wednesday, falling 38% in intraday trade after the company disclosed that the U.S. Food and Drug Administration had recommended it run a second Phase 3 trial of an ovarian cancer drug......»»

Shares of ImmunoGen, Inc. fell 32% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration recommended conducting a new Phase 3 trial of its ovarian cancer d.....»»

Shares of biotech Cytokinetics Inc. plunged 19% in premarket trade Monday after the comp.....»»

Shares in drug maker Daiichi Sankyo soared after AstraZeneca agreed to pay the Japanese company up to $6.9 billion as part of an agreement to develop and market a potentially "transformative" cancer treatment......»»